Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in adults with obesity, with...

WEDNESDAY, June 25, 2025 -- For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is...

WEDNESDAY, June 25, 2025 -- For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is...

BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.

MONDAY, June 23, 2025 -- For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon like...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial...

TUESDAY, July 1, 2025 -- For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with...

TUESDAY, July 1, 2025 -- For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with...